While the causal impact of the potential cellular sources of MIF-2 expression (immune cells, VSMCs, hepatocytes) is currently unclear and should be an important aim of future studies, our data overall imply that MIF-2 may be a promising therapeutic target in atherosclerosis, vascular inflammation, and associated metabolic conditions. The gene discussed is DDT; the disease is atherosclerosis.